Skip to main content

Recent News

  • Jan 20, 2021
    ILD damage fibrosis path

    A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.

    Read Article
Epidemiologic study of #SLE from CDC & lupus registries estimates there are 204,295 SLE pts in USA (2018).

Dr. John Cush @RheumNow (  View Tweet)

Jan 21, 2021
My note to the FDA staff: https://t.co/n2Pr2Kzrre
Dr. Janet Woodcock @DrWoodcockFDA (  View Tweet)
Jan 21, 2021
Toci led to poorer outcomes in this study. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ https://t.co/95zaq2CEUU

Dr Philip Robinson @philipcrobinson (  View Tweet)

Jan 21, 2021
UTSW Rheum Grand Rounds - IgG4 Dz - Plasmablasts may be a useful biomarker; but is not generally available in clinical labs (must be done on fresh whole blood) @UTSWIMchief https://t.co/GlEKw0KD3O
Dr. John Cush @RheumNow (  View Tweet)
Jan 21, 2021
UTSW Rheum Grand Rounds - IgG4 Dz common lab findings: hypergammaglobulinemia is common but elevated ESR/CRP are not. Most have elevated IgG4 serum levels @UTSWIMchief https://t.co/wR5FEqZTsX
Dr. John Cush @RheumNow (  View Tweet)
Jan 21, 2021
UTSW Rheum Grand Rounds - IgG4 Dz commonly presents as major salivary and lacrimal gland enlargement, orbital disease, autoimmune pancreatitis, retroperitoneal (mass) fibrosis or tubulointerstitial nephritis. @UTSWIMchief

Dr. John Cush @RheumNow (  View Tweet)

Jan 21, 2021
UTSW Rheum Grand Rounds - IgG4 Dz renal involvement; most common is tubulointerstitial nephritis @UTSWIMchief https://t.co/q8dZbgmvfK
Dr. John Cush @RheumNow (  View Tweet)
Jan 21, 2021
UTSW Rheum Grand Rounds - Dr. Andres Quiceno on "IgG4 related Disease" Histologic criteria req >40% on IgG4/IgG cells @UTSWIMchief https://t.co/2kOioCdFiM
Dr. John Cush @RheumNow (  View Tweet)
Jan 21, 2021
Being "busy" is about priorties and productivity.

Dr. John Cush @RheumNow (  View Tweet)

Jan 21, 2021
Inequities in Telemedicine During COVID-19 Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began but what if you don't have access to reliable technology?
Dr. John Cush @RheumNow (  View Tweet)
Jan 21, 2021

Low Risk of TB with Secukinumab

Jan 20, 2021

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were found. 

Read Article
Osteoporosis in Men - is often unrecognized till they fracture.

Dr. John Cush @RheumNow (  View Tweet)

Jan 20, 2021
ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at #ACR20?
Dr. John Cush @RheumNow (  View Tweet)
Jan 20, 2021
Results from Cohort Hip & Cohort Knee study (early symptomatic hip OA pts) finds that 1/9 went on to receive hip replacement during the 10-year follow-up.
Dr. John Cush @RheumNow (  View Tweet)
Jan 20, 2021
Dr Stanley Cohen has written a nice review of VTE with JAK inhibitors, points out that little/no risk during developmental trials, is not the same as a low risk seen with long term use in real world patients (older, higher BMI, more activity) https://t.co/0utVMqHdf

Dr. John Cush @RheumNow (  View Tweet)

Jan 20, 2021
Swedish Rheumatology Quality Register study of 46316 RA pts (322601 visits) shows RA has a higher risk of venous thromboembolism (RR 1.88;95% CI 1.65, 2.15) & this increased with disease activity (RR=2.03;1.73 to 2.38) (compared to remission).

Dr. John Cush @RheumNow (  View Tweet)

Jan 20, 2021
Dr. Janet Woodcock has been appointed the interim head of the FDA. President Biden has yet to nominate a new FDA commissioner. Dr. Woodcock is a rheumatologist and current Director of CDER at the FDA .https://t.co/Wk0auZ2pn1

Dr. John Cush @RheumNow (  View Tweet)

Jan 20, 2021
Sign up to attend RheumNow Live--March 20 and 21. CME credits available https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d
Dr. John Cush @RheumNow (  View Tweet)
Jan 20, 2021

Factors Predictive of SLE Flare After HCQ Taper/Discontinuation

MedPage Today
Jan 19, 2021

The benefits of hydroxychloroquine in lupus are many, but if you were to withdraw HCQ? A recent study of five Canadian cohorts, suggests that certain baseline variables, including age, race, and steroid use,  were predictive of flare in patients with SLE who tapered or discontinued treatment with hydroxychloroquine.

Read Article
ACR Convergence 2020 Fireside Chats – top presentations in Still’s disease Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at ACR Convergence 2020?
Dr. John Cush @RheumNow (  View Tweet)
Jan 19, 2021
×